Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -27.0%
- Operating Margin Trend +5.81 pp/yr
TNGX
Tango Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -39.0%
- 5yr Share-Count CAGR 5.8%
Growth Quality
Weight: 35%
A+
94
- 5yr Revenue CAGR 52.1%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -300.2%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 42.44
Stability
Weight: 5%
C
54
- Negative-Revenue Years (5) 1/5
- Piotroski F-Score 3
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 3 gurus held; 1 trimmed; 3 full exits.
- Holders
- 1 -2
- Avg Δ position
- -44.1%
- New buys
- 0
- Full exits
- 3
- Cooperman sold -100%
- Greenblatt sold -100%
- Laffont sold -100%